91
Views
5
CrossRef citations to date
0
Altmetric
Original Research

Adherence to oral anticoagulant therapy in secondary stroke prevention – impact of the novel oral anticoagulants

, , , , , , , , & show all
Pages 1695-1705 | Published online: 23 Nov 2015

Figures & data

Figure 1 Flow chart illustrating the participation of patients who had an OAT installed at discharge from the stroke unit after stroke or transient ischemic attack.

Notes: aBy patient or next-of-kin. The rates indicated as % refer to the initial secondary prevention cohort of n=324 patients. To obtain the fatality corrected response rate, we calculated the ratio between completed questionnaires and the number of the entire secondary prevention cohort (n=324) minus the patients that were reported as deceased at 1 year (n=39).
Abbreviation: OAT, oral anticoagulant therapy.
Figure 1 Flow chart illustrating the participation of patients who had an OAT installed at discharge from the stroke unit after stroke or transient ischemic attack.

Figure 2 Global neurological function of the patients at 1-year follow-up.

Note: Graded on the modified Rankin Scale score (mRS) according to the written or oral answers of patients and/or their next-of-kin. (A) All participating patients, (B) by mode of participation.
Figure 2 Global neurological function of the patients at 1-year follow-up.

Table 1 Demographic characterization of patients’ anticoagulated with VKA or NOAC at discharge from our stroke units

Table 2 Persistence to OAT at 1 year by specific choice of OAT at discharge

Figure 3 Patients’ self-reported adherence assessed with the MMAS-8.

Notes: Only the patients who had returned the written questionnaire and had filled out the Morisky score at the end of the 1-year follow-up period (n=142) were included in the analysis, excluding patients or next-of-kin who provided their information via telephone interview.
Abbreviations: MMAS-8, eight-point Morisky Medication Adherence Scale; VKA, vitamin K antagonists.
Figure 3 Patients’ self-reported adherence assessed with the MMAS-8.

Figure 4 Multivariate analysis of factors influencing adherence to OAT in stroke patients.

Notes: We analyzed all patients with available written or oral questionnaire (n=209) and adjusted for age, sex, mRS at discharge, and at 1-year follow-up and choice of OAT at discharge. *P<0.05.
Abbreviations: CI, confidence interval; DOAC, direct oral anticoagulants; mRS, modified Ranking Scale score; OAT, oral anticoagulant therapy; OR, odds ratio; VKA, vitamin K antagonists.
Figure 4 Multivariate analysis of factors influencing adherence to OAT in stroke patients.

Table 3 Univariate comparison of patient characteristics between persistent and nonpersistent patients

Table S1 Demographic characterization by specific choice of OAT

Table S2 Reasons to switch therapy during the 1-year follow-up period